Prime Medicine (NYSE:PRME) Receives “Outperform” Rating from Wedbush
Wedbush reaffirmed their outperform rating on shares of Prime Medicine (NYSE:PRME – Free Report) in a research note published on Tuesday,RTT News reports. The firm currently has a $13.00 price target on the stock, up from their prior price target of $12.00. A number of other research firms have also recently commented on PRME. StockNews.com […]
Wedbush reaffirmed their outperform rating on shares of Prime Medicine (NYSE:PRME – Free Report) in a research note published on Tuesday,RTT News reports. The firm currently has a $13.00 price target on the stock, up from their prior price target of $12.00. A number of other research firms have also recently commented on PRME. StockNews.com […]
